Stanford University (Global Rights to Novel VT-109) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Stanford University (Global Rights to Novel VT-109) General Information
Description
Global rights of the novel next-generation fusion protein targeting BAFF and APRIL.
Contact Information
Corporate Office
- United States
Corporate Office
- United States
Stanford University (Global Rights to Novel VT-109) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Stanford University (Global Rights to Novel VT-109) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Stanford University (Global Rights to Novel VT-109) FAQs
-
Where is Stanford University (Global Rights to Novel VT-109) headquartered?
Stanford University (Global Rights to Novel VT-109) is headquartered in .
-
What industry is Stanford University (Global Rights to Novel VT-109) in?
Stanford University (Global Rights to Novel VT-109)’s primary industry is Buildings and Property.
-
Is Stanford University (Global Rights to Novel VT-109) a private or public company?
Stanford University (Global Rights to Novel VT-109) is a Private company.
-
What is the current valuation of Stanford University (Global Rights to Novel VT-109)?
The current valuation of Stanford University (Global Rights to Novel VT-109) is .
-
What is Stanford University (Global Rights to Novel VT-109)’s current revenue?
The current revenue for Stanford University (Global Rights to Novel VT-109) is .
-
Who are Stanford University (Global Rights to Novel VT-109)’s investors?
Stanford University has invested in Stanford University (Global Rights to Novel VT-109).
-
When was Stanford University (Global Rights to Novel VT-109) acquired?
Stanford University (Global Rights to Novel VT-109) was acquired on 13-Jan-2025.
-
Who acquired Stanford University (Global Rights to Novel VT-109)?
Stanford University (Global Rights to Novel VT-109) was acquired by Vera Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process